{"id":5485,"date":"2019-07-16T23:43:48","date_gmt":"2019-07-16T18:13:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5485"},"modified":"2021-07-24T12:57:27","modified_gmt":"2021-07-24T07:27:27","slug":"recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos","title":{"rendered":"Recursion Pharmaceuticals nets USD 121M; Bayer&#8217;s MRI agent gets a nod"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>AI-powered drug-maker\nRecursion Pharmaceuticals secures USD 121 M to accelerate its clinical programs\n<\/strong><\/h4>\n\n\n\n<p>Recursion Pharmaceuticals, a\nnext-gen biopharma company, <strong>has raised USD 121 Million in Series C\nfinancing.<\/strong> The Series C round was led by Baillie Gifford&#8217;s flagship\ninvestment trust, Scottish Mortgage Investment Trust PLC, with participation by\nnew institutional investors Intermountain Ventures, Regents of the University\nof Minnesota, Texas Tech University System, and few additional angel investors.\nCombining artificial intelligence with drug discovery, the company plan to use\nthe proceeds to fuel its drug discovery platform along with discovering and\nadding new chemical entities and predicting safety pharmacology. The company\nalso plans to advance its already growing pipeline for <strong>cavernous cerebral\nmalformation<\/strong> and <strong>neurofibromatosis type 2.<\/strong> At present, the neurofibromatosis\ntype 2 therapy market has no effective medical therapies that can assure\ncomplete cure with no or minimal side effects. While surgeries can obliterate\nthe tumour, but they involve the risk of nerve damage and drug therapy in\ncombination with chemotherapy does not ascertain 100% effective tumour removal.\nHowever, pharma companies such as <strong>AstraZeneca<\/strong>, <strong>Array<\/strong> <strong>Biopharma<\/strong>,\n<strong>SpringWorks<\/strong> <strong>Therapeutics<\/strong> etc. are actively working towards the\ndevelopment of potential therapies to meet the neurofibromatosis 2 unmet\nmedical needs of the currently used therapeutics. As per DelveInsight\nestimates, the launch of emerging therapies such <strong>Selumetinib<\/strong> (AstraZeneca),\n<strong>Binimetinib<\/strong> (Array Biopharma) and <strong>PD-0325901<\/strong> (SpringWorks\nTherapeutics) will significantly impact the Neurofibromatosis 2 market during\nthe forecast period (2019-2028).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Bayer&#8217;s Gadavist MRI agent\ngets FDA thumbs up to treat adult patients with known or suspected coronary\nartery disease<\/strong><\/h4>\n\n\n\n<p>The US FDA today approved <strong>Bayer&#8217;s Gadavist (gadobutrol) <\/strong>injection for gauging cardiac magnetic resonance (MR) imaging to evaluate myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected <strong>coronary artery disease (CAD).<\/strong> Coronary artery disease is the most common and leading cause of death in the United States in both men and women. <br><strong>Gadavist<\/strong> is the first, and the only FDA approved gadolinium-based contrast agent, promising to help clear blood supply of the heart muscles and assess the rates of myocardial perfusion at rest and during stress. The injection was first approved in the U.S. in the year 2011 for intravenous use in magnetic resonance (MR) imaging to detect and visualize areas with disrupted blood-brain barrier and\/or abnormal vascularity of the central nervous system. Later on, in 2014, the FDA expanded its approval for MR of breast cancer to assess the extent of malignancy.&nbsp; In the year 2016, in the US, Gadavist received a green signal to evaluate known or <strong>suspected supra-aortic <\/strong>or<strong> renal artery diseases<\/strong>. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Gilead gains broader access to\nGalapagos pipeline, inks USD 5 M upfront deal <\/strong><\/h4>\n\n\n\n<p><strong>Gilead Sciences<\/strong> and <strong>Galapagos NV<\/strong> have entered into a 10-year collaboration to gain and expand their clinical portfolio mutually. This agreement will help Gilead gain access to an innovative collection of six clinical-phase assets, 20 preclinical programs, and a drug discovery platform in the form Galapagos with an exclusive product licensing right outside Europe. On the other hand, Galapagos may receive a lumpsum amount of <strong>USD 3.95 Million upfront<\/strong> and plans to use the capital received to accelerate its R&amp;D programs. <br>Moreover, Gilead is making a <strong>USD 1.1 Billion equity investment<\/strong> in Galapagos, thus getting a hold on Galapagos&#8217; pipeline. The drug makers are also thinking to revise certain specific terms regarding <strong>filgotinib<\/strong>, the lead candidate under trials for treating advanced <strong>rheumatoid arthritis<\/strong> and other inflammatory diseases to provide Galapagos with a broader commercialization role in Europe. Gilead plans to invest more in Galapagos&#8217;s candidates GLPG1690 and GLPG1972, already under trials, if they produce positive results in treating <strong>idiopathic pulmonary fibrosis<\/strong> and <strong>osteoarthritis,<\/strong> respectively. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AI-powered drug-maker Recursion Pharmaceuticals secures USD 121 M to accelerate its clinical programs Recursion Pharmaceuticals, a next-gen biopharma company, has raised USD 121 Million in Series C financing. The Series C round was led by Baillie Gifford&#8217;s flagship investment trust, Scottish Mortgage Investment Trust PLC, with participation by new institutional investors Intermountain Ventures, Regents of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[107,17739],"industry":[17225],"therapeutic_areas":[17242,17238],"class_list":["post-5485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bayer","tag-recursion-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recursion Pharmaceuticals nets USD 121M; Bayer&#039;s MRI agent gets a nod<\/title>\n<meta name=\"description\" content=\"The US FDA today approved Bayer&#039;s Gadavist (gadobutrol) injection for gauging cardiac magnetic resonance (MR) imaging to evaluate myocardial perfusion...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recursion Pharmaceuticals nets USD 121M; Bayer&#039;s MRI agent gets a nod\" \/>\n<meta property=\"og:description\" content=\"The US FDA today approved Bayer&#039;s Gadavist (gadobutrol) injection for gauging cardiac magnetic resonance (MR) imaging to evaluate myocardial perfusion...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-16T18:13:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod","description":"The US FDA today approved Bayer's Gadavist (gadobutrol) injection for gauging cardiac magnetic resonance (MR) imaging to evaluate myocardial perfusion...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos","og_locale":"en_US","og_type":"article","og_title":"Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod","og_description":"The US FDA today approved Bayer's Gadavist (gadobutrol) injection for gauging cardiac magnetic resonance (MR) imaging to evaluate myocardial perfusion...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-16T18:13:48+00:00","article_modified_time":"2021-07-24T07:27:27+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos","name":"Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","datePublished":"2019-07-16T18:13:48+00:00","dateModified":"2021-07-24T07:27:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The US FDA today approved Bayer's Gadavist (gadobutrol) injection for gauging cardiac magnetic resonance (MR) imaging to evaluate myocardial perfusion...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-recursion-pharmaceuticals-bayer-gilead-galapagos#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","width":647,"height":345,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Recursion Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Recursion Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 16, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 16, 2019 11:43 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5485"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5485\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5080"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5485"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5485"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}